Copyright
©The Author(s) 2019.
World J Clin Oncol. Mar 24, 2019; 10(3): 136-148
Published online Mar 24, 2019. doi: 10.5306/wjco.v10.i3.136
Published online Mar 24, 2019. doi: 10.5306/wjco.v10.i3.136
Table 5 Results from Logistic regression of lymph node, tumor stage and recurrence status on fibroblast growth factor receptor 4 genotype (P < 0.0001)
| Fibroblast growth factor receptor 4 genotype | Coeff. | Std. Err. | z | P >|z| | Odds ratio | 95% CI |
| Recurrence status | 0.440 | 0.1693179 | 2.6 | 0.009 | 4.37 | 0.1080489-0.7717629 |
| positive lymph nodes | 1.972 | 0.1585958 | 12.44 | 0.0001 | 14.43 | 1.661438-2.283122 |
| Tumor stage | -1,721 | 0.2903174 | -5.93 | 0.0001 | 0.24 | -2.29047-1.152446 |
| constant | -1.826 | 0.1234243 | -14.79 | 0.0001 | -2.067534-1.58372 |
- Citation: Wimmer E, Ihrler S, Gires O, Streit S, Issing W, Bergmann C. Fibroblast growth factor receptor 4 single nucleotide polymorphism Gly388Arg in head and neck carcinomas. World J Clin Oncol 2019; 10(3): 136-148
- URL: https://www.wjgnet.com/2218-4333/full/v10/i3/136.htm
- DOI: https://dx.doi.org/10.5306/wjco.v10.i3.136